Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals (XENE) is a clinical-stage biopharmaceutical company pioneering neuroscience therapies through its innovative extreme genetics platform. This page serves as the definitive source for verified company news, providing investors and researchers with timely updates on therapeutic advancements and strategic developments.
Access curated press releases covering clinical trial milestones, regulatory updates, and research collaborations. Our news collection focuses on XENE's work identifying novel drug targets through genetic analysis of severe disorders, particularly in neurology and psychiatry. Track progress across their pipeline of precision therapies targeting ion channels and neurological pathways.
Key updates include phase trial results, patent filings, executive appointments, and scientific presentations. All content is vetted for accuracy and relevance to investment research. Bookmark this page for efficient monitoring of XENE's progress in genetic-driven drug discovery and partnership announcements within the neuroscience sector.
Xenon Pharmaceuticals (NASDAQ:XENE) has advanced its XEN1101 Phase 3 epilepsy program, with ongoing trials including X-TOLE2, X-TOLE3, and X-ACKT. The company expects topline results from the XEN1101 Phase 2 X-NOVA study in major depressive disorder by Q3 2023. Financially, Xenon reported a net loss of $125.4 million for 2022, an increase from $78.9 million in 2021, due to higher R&D and G&A expenses. Cash reserves as of December 31, 2022, were $720.8 million, enough to fund operations until 2026. The company aims to address unmet needs in epilepsy and mental health disorders with its innovative therapies.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its fourth quarter and full year 2022 financial results on March 1, 2023, after U.S. markets close. The company specializes in developing neurology-focused biopharmaceuticals, particularly for epilepsy. A conference call will be held at 4:30 PM ET the same day, with dial-in numbers provided for both domestic and international callers. Additionally, a live audio webcast will be available in the Investors section of their website, offering a replay option post-event.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its participation in the virtual SVB Securities Global Biopharma Conference from February 14-16, 2023. A key event will be a fireside chat on February 15, 2023, at 3:00 PM ET, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO.
A live webcast will be available on their website, with a replay posted after the event. Xenon focuses on developing innovative therapeutics for neurological disorders, particularly epilepsy. More information can be found at www.xenon-pharma.com.
Xenon Pharmaceuticals (NASDAQ:XENE) announced advancements in its XEN1101 Phase 3 epilepsy program, now active in both focal onset seizures and primary generalized tonic clonic seizures. The company is financially robust, expecting to fund its operations until 2026. The X-TOLE2 study for focal seizures is underway, with the newly initiated X-ACKT trial targeting generalized seizures. Data from the X-NOVA study on major depressive disorder is anticipated in Q3 2023, alongside collaboration updates with Neurocrine Biosciences.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The presentation is scheduled for January 9, 2023, at 7:30 am PT (10:30 am ET), led by President and CEO Ian Mortimer. Investors can access a live webcast of the presentation on the company’s website, with a replay available afterward. Xenon focuses on developing innovative treatments for neurological disorders, particularly epilepsy, aiming to address significant unmet medical needs.
Xenon Pharmaceuticals (Nasdaq:XENE) presented positive interim data from the Phase 2b open-label extension of its XEN1101 clinical trial for focal onset seizures at the American Epilepsy Society (AES 2022). Key findings show sustained seizure reduction of 80%-90%, with 17.5% and 10.5% of patients achieving 6- and 12-month seizure freedom, respectively. XEN1101 was well-tolerated, and the ongoing Phase 3 program aims to confirm these results. The trial included a difficult-to-treat patient population, suggesting robust efficacy that may enhance XEN1101's market potential.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in one-on-one investor meetings and a fireside chat at the Bank of America Securities Biotech SMID Cap Conference 2022. The event will be held virtually on December 7-8, 2022. Ian Mortimer, President and CEO, along with Sherry Aulin, CFO, will present on December 7 at 1:10 pm Eastern Time. A webcast of the presentation will be accessible on the company’s website for later viewing. Xenon Pharmaceuticals focuses on developing innovative therapies for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) has announced that President Ian Mortimer and CFO Sherry Aulin will participate in fireside chats and one-on-one meetings at upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 14, the Stifel 2022 Healthcare Conference on November 15, and the Jefferies London Healthcare Conference on November 17. These presentations aim to engage investors and provide insights into the company’s developments in neurology therapeutics. Additional information can be found on their investors' website.
Xenon Pharmaceuticals has launched its Phase 3 program for XEN1101, initiating the X-TOLE2 clinical trial focused on treating epilepsy. The company maintains a strong financial position with approximately $752 million in cash, ensuring funding for operations through 2026. Despite a significant drop in third-quarter revenue from $8.1 million to $0.1 million due to the end of a collaboration with Neurocrine Biosciences and no milestone payments, R&D expenses have increased to $29.4 million. A conference call to discuss these updates is scheduled for today.
Xenon Pharmaceuticals (NASDAQ:XENE) appointed Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. DiFabio joins during a critical time as the company advances multiple late-stage clinical programs aimed at commercializing epilepsy therapeutics. With extensive experience in the life sciences sector, she previously held senior legal roles at various biopharmaceutical firms, including Biogen and Repertoire Immune Medicines. Her role will focus on enhancing Xenon’s legal framework and supporting its strategic goals in neurology therapeutics.
FAQ
What is the current stock price of Xenon Pharmaceut (XENE)?
What is the market cap of Xenon Pharmaceut (XENE)?
